217661-27-3

Basic information

• Product Name: 2-CYANO-4-FLUOROBENZYL BROMIDE
• Synonyms: 2-(broMoMethyl)-5-fluorobenzonitrile;2-CYANO-4-FLUOROBENZYL BROMIDE
• CAS NO: 217661-27-3
• Molecular Formula: C₈H₅BrFN
• Molecular Weight: 214.0344
• Mol File: 217661-27-3.mol

Chemical Properties

• Melting Point: 64.9-65.9 °C
• Boiling Point: 263.576 °C at 760 mmHg
• Flash Point: 113.207 °C
• Appearance: /
• Density: 1.591 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-CYANO-4-FLUOROBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYANO-4-FLUOROBENZYL BROMIDE(217661-27-3)
• EPA Substance Registry System: 2-CYANO-4-FLUOROBENZYL BROMIDE(217661-27-3)

Safety Data

• Hazardous Substances Data: 217661-27-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyano-4-Fluorobenzyl Bromide is used as a chemical reagent for the synthesis of pharmaceutical products. Its unique structural composition allows it to be a key component in the creation of various medications, contributing to the development of new and improved treatments.
Used in Organic Chemistry Research:
In the field of organic chemistry, 2-Cyano-4-Fluorobenzyl Bromide is used as a reagent in various chemical reactions. Its reactivity and structural properties make it a valuable tool for researchers in exploring new reaction pathways and developing novel compounds with potential applications in various industries.

InChI:InChI=1/C8H5BrFN/c9-4-6-1-2-8(10)3-7(6)5-11/h1-3H,4H2

Upstream product

• 77532-79-7 3-fluoro-6-methylbenzonitrile 

Downstream Products

• 870562-69-9 2-((1,3-dioxoisoindolin-2-yl)methyl)-5-fluorobenzonitrile 
• 883996-97-2 2-((5-bromo-1,6-dihydro-1-isopropyl-2-(methylthio)-6-oxopyrimidin-4-yloxy)methyl)-5-fluorobenzonitrile 
• 635721-24-3 2-[3-(2-Butynyl)-4-oxo-2-(piperazin-1-yl)-3,4-dihydroimidazo[4,5-d]pyridazin-5-ylmethyl]-5-fluorobenzonitrile trifluoroacetate 
• 945995-09-5 2-(bromomethyl)-5-fluorobenzaldehyde 
• 945996-03-2 methyl 3-{4-[(2-cyano-4-fluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-1(6H)-yl}-4-methylbenzoate 
• 945995-98-2 methyl 3-(4-(2-cyano-4-fluorobenzyloxy)-3-chloro-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate 
• 945995-99-3 methyl 3-(4-(2-cyano-4-fluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate 
• 1276041-95-2 2-benzyl-5-fluorobenzonitrile 
• 1276042-13-7 (2-benzoyl-5-fluorophenyl)(p-tolyl)methanone 
• 1293388-04-1 5-fluoro-2-[(6-oxo-7-{[2-(trimethylsilyl)ethoxy]methoxy}-6,7,8,9-tetrahydro-3H-pyrrolo[2,3-c][1,7]naphthyridin-3-yl)methyl]benzonitrile 
• 1432518-78-9 (2Z)-2-({2-[2-(benzenesulfonyl)ethyl]-5-fluorophenyl}methyl)but-2-ene-1,4-diol 
• 1432518-79-0 (6R)-8-(benzenesulfonyl)-13-fluoro-6-{[(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl]-xy}-5-oxatricyclo[8.4.0.0]tetradeca-1⁽¹⁴⁾,2,7,10,12-pentaen-4-one 
• 1432519-36-2 (3S,6R,7R)-8,8-bis(benzenesulfonyl)-13-fluoro-6-{[(1R,2S,5R)-5methyl-2-(propan-2-yl)cyclohexyl]oxy}-5-oxatricyclo[8.4.0.03,7]tetradeca-1⁽¹⁴⁾,10,12-trien-4-one 
• 1432519-37-3 (7R,8S)-6,6-bis{(benzenesulfonyl)-2-fluoro-8-(hydroxymethyl)6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl}methanol 

Relevant articles and documents

INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF

The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Substituted 5,6,11,12-tetradehydrodibenzo[ a, e ]cyclooctenes: Syntheses, properties, and DFT studies of substituted sondheimer-wong diynes

Highly strained cyclic acetylenes 5,6,11,12-tetradehydrodibenzo[a,e]cyclooctenes (Sondheimer-Wong diynes) having various substituents on their benzene rings were synthesized successfully by one-pot treatment of the corresponding formyl sulfones with diethyl chlorophosphate/lithium hexamethyldisilazide (LiHMDS) and then lithium diisopropylamide (LDA). When mixtures of two types of formyl sulfones bearing different substituents were subjected to this protocol, the unsymmetrically substituted Sondheimer-Wong diynes could be synthesized in a stepwise manner by isolation of the heterocoupled vinyl sulfone intermediates followed by their treatment with LDA. The UV-vis absorption spectra and cyclic voltammograms of the substituted Sondheimer-Wong diynes were recorded. The electronic effect of substituents on the diynes was investigated in their click reactions and nucleophilic and electrophilic additions.

Asymmetric synthesis of carbocycles: Use of intramolecular conjugate displacement

Intramolecular conjugate displacement (ICD), the process illustrated in eqn (1), has been applied to the Morita-Baylis-Hillman adducts formed from (5S)-5-(l-menthyloxy)-2(5H)-furanone and aldehydes that are substituted in the γ- or δ-position by geminal phenylthio groups. When the initial Morita-Baylis-Hillman alcohols are acetylated and oxidized to geminal sulfones, deprotonation causes ring closure by ICD (2.5→2.6). Hydrogenation, DIBAL-H reduction and desulfonylation releases an optically pure carbocycle. The Royal Society of Chemistry 2013.

Copper-catalyzed benzylic C-H oxygenation under an oxygen atmosphere via N-H imines as an intramolecular directing group

Copper-catalyzed benzylic C-H oxygenation under an oxygen atmosphere was developed starting from carbonitriles and Grignard reagents via N-H imine intermediates. The present process is characterized by the following two-step sequence in a one-pot manner: (1) addition of Grignard reagents to carbonitriles to form N-H imines and (2) benzylic C-H oxygenation (C=O bond formation) triggered by 1,5-hydrogen atom transfer with transient iminyl copper species.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV

The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.

Integrase inhibitor compounds

Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

HIV integrase inhibitors

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

HIV INTEGRASE INHIBITORS

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.